Literature DB >> 1896958

Specific quantification of heparin-dependent antibodies for the diagnosis of heparin-associated thrombocytopenia using an enzyme-linked immunosorbent assay.

Y Gruel1, A Rupin, L Darnige, P Moalic-Reverdiau, P Poumier-Gaschard, C Binet, P Bardos, J Leroy.   

Abstract

In order to specifically detect heparin-dependent antibodies in patients with suspected heparin-associated thrombocytopenia (HAT), an adapted ELISA test was developed. Serum-platelet bindable IgG (SPb-IgG) were measured in the absence and in the presence of heparin in the sera from a/ 25 normal controls, 25 patients treated by heparin without thrombocytopenia, 29 thrombocytopenic patients not receiving heparin and b/ 12 patients with confirmed HAT. In the absence of heparin, the 12 HAT sera showed normal or elevated SPb-IgG levels (range = 10.4-36 Arbitrary Units or AU) as compared to healthy controls (8-17.1 AU). After coincubation of HAT sera with heparin (0.25, 0.50, 0.75, and 1 IU/ml), SPb-IgG levels were consistently elevated (range = 22.8-150 AU), and this increase in IgG binding (equal in mean to 200%) was always inhibited with 5 IU/ml of heparin. In contrast, a mean maximum increase in SPblgG levels of only 20% was registered in all control groups whatever the tested heparin concentration. Thus, this ELISA allows the specific diagnosis of HAT by demonstrating a serum IgG binding on platelets only in the presence of therapeutic concentrations of heparin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1896958     DOI: 10.1016/0049-3848(91)90011-k

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

Review 1.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.

Authors:  A Greinacher; W Drost; I Michels; J Leitl; M Gottsmann; H J Kohl; M Glaser; C Mueller-Eckhardt
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.